Covetrus Inc (NASDAQ:CVET) has earned a consensus rating of “Hold” from the eight analysts that are presently covering the stock, MarketBeat Ratings reports. Five investment analysts have rated the stock with a hold rating and three have issued a buy rating on the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $36.67.
A number of analysts have weighed in on CVET shares. Credit Suisse Group started coverage on Covetrus in a research note on Thursday, April 4th. They issued a “neutral” rating and a $35.00 price target on the stock. Cleveland Research started coverage on Covetrus in a research note on Friday, May 10th. They issued a “hold” rating on the stock. Guggenheim restated a “buy” rating and issued a $95.00 price target (up from $90.00) on shares of VF in a research note on Thursday, May 23rd. Stifel Nicolaus set a $154.00 price target on argenx and gave the company a “buy” rating in a research note on Wednesday, May 22nd. Finally, Zacks Investment Research cut H&E Equipment Services from a “hold” rating to a “sell” rating in a research note on Wednesday, July 17th.
In other news, insider Timothy Ludlow sold 81,498 shares of Covetrus stock in a transaction dated Friday, May 17th. The stock was sold at an average price of $28.01, for a total transaction of $2,282,758.98. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Betsy S. Atkins sold 150,845 shares of Covetrus stock in a transaction dated Friday, May 17th. The stock was sold at an average price of $27.80, for a total value of $4,193,491.00. The disclosure for this sale can be found here. Insiders have sold 233,028 shares of company stock worth $6,495,656 in the last quarter.
Covetrus (NASDAQ:CVET) last posted its quarterly earnings results on Wednesday, May 15th. The company reported $0.14 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.17 by ($0.03). The business had revenue of $941.00 million during the quarter, compared to the consensus estimate of $993.41 million. During the same quarter in the previous year, the company posted $0.18 EPS. Covetrus’s quarterly revenue was down .6% compared to the same quarter last year. On average, research analysts expect that Covetrus will post 0.63 earnings per share for the current fiscal year.
Covetrus Company Profile
Covetrus, Inc engages in developing technologies and services for animal health industry. It also provides products, software, and services to help drive improved patient health, strong client relationships, and successful financial outcomes for veterinary professionals. The company was founded on April 13, 2018 and is headquartered in Melville, NY.
Featured Article: Net Margin – Understanding the Different Kinds of Profit
Receive News & Ratings for Covetrus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Covetrus and related companies with MarketBeat.com's FREE daily email newsletter.